Novartis lung cancer drug gets priority U.S. review

Novartis has won fast-track U.S. regulatory review for capmatinib (INC280) in a hard-to-treat form of lung cancer, the Swiss drugmaker said on Tuesday.
Capmatinib is a MET inhibitor being evaluated as a treatment for first-line and previously treated patients with locally advanced or metastatic MET exon 14 skipping (METex14) mutated non-small cell lung cancer.
“If approved, capmatinib will be the first therapy to specifically target METex14 mutated advanced lung cancer, a type of lung cancer with a particularly poor prognosis,” Novartis said in a statement.
https://www.reuters.com/article/us-novartis-cancer/novartis-lung-cancer-drug-gets-priority-u-s-review-idUSKBN2050J9